LENZ LENZ Pharma: Enterprise Value to EBITDA Ratio

The success of LENZ Therapeutics, Inc. (LENZ) depends on FDA approval of its presbyopia drug and the market acceptance of the product. Meanwhile, the company relies on outsourced manufacturing and utilizes existing cash to fund development. This chart provided by GURU.Markets clearly demonstrates the valuation dynamics based on the EV/EBITDA multiple, while 0.00 expresses the current value of the metric.

This indicator compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, allowing for an assessment of the real cost of capital relative to the generated cash flow. By analyzing the EV/EBITDA multiple inclusive of net debt, an investor in LENZ Therapeutics, Inc. (LENZ) can track the extent to which current commercialization costs for presbyopia drops are already priced into the asset's market valuation.